REAC efficacy in clinical assessments of symptoms represented by

REAC efficacy in clinical assessments of symptoms represented by

4.8
(672)
Écrire un avis
Plus
€ 27.99
Ajouter au panier
En Stock
Description

Recommendations for Interpreting E-RS:COPD Scores

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma - ScienceDirect

Frontiers Presentation and physical therapy management of upper cervical instability in patients with symptomatic generalized joint hypermobility: International expert consensus recommendations

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet

Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial - eClinicalMedicine

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

Current Oncology, Free Full-Text

PSA6669 - SECTION 5: CLINICAL IMPRESSION

Frontiers Neurologic Assessment of the Neurocritical Care Patient

Development, psychometric evaluation and cognitive debriefing of the rheumatoid arthritis symptom and impact questionnaire (RASIQ), Journal of Patient-Reported Outcomes

Transtheoretical model - Wikipedia

Clinical Spotlight Review: Management of Choledocholithiasis - A SAGES Publication

Influenza Antiviral Medications: Summary for Clinicians

Regeneration and Assessment of the Endothelial Glycocalyx To Address Cardiovascular Disease

Recommendations for Interpreting E-RS:COPD Scores